

DAFTAR PUSTAKA

1. Downie L, Gallibois C, Parekh R, Noone D. Nephrotic syndrome in infants and children: pathophysiology and management. *Paediatrics and International Child Health*. 2017; 248 - 258
2. Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR. Clinical Practice Guideline for Screening and Management. *American Academy of Pediatrics*. 2017;40(3):1-74.
3. Unit Kerja Koordinasi Nefrologi Ikatan Dokter Anak Indonesia. *Konsensus Tata Laksana Sindrom Nefrotik Idiopatik pada Anak*. Edisi Kedua. Badan Penerbit Ikatan Dokter Anak Indonesia, 2012.
4. Abdel-Hafez MA, Abou-El-Hana NM, Erfan AA, El-Gamasy M, Abdel-Nabi H. Predictive risk factors of steroid dependent nephrotic syndrome in children. *J Nephropathol*. 2017;6(3):180-186.
5. Andersen RF, Thrane N, Noergaard K, Rytter L, Jespersen B, Rittig S. Early age at debut is a predictor of steroid-dependent and frequent relapsing nephrotic syndrome. *Pediatr Nephrol* (2010) 25:1299–1304
6. Aydin M, Franke I, Kurylowicz L, Ganschow R, Lentze M, Born M, et al. The long-term outcome of childhood nephrotic syndrome in Germany: a cross-sectional study. *Clinical and Experimental Nephrology*. 2019;1-13.
7. Yap HK, Han EJS, Heng CK, Gong WK. Risk factors for steroid dependency in children with idiopathic nephrotic syndrome. *Pediatr Nephrol* (2001) 16:1049–1052.
8. Siegel NJ, Gaudio KM, Krassner LS, McDonald BM, Anderson FP, Kashgarian M. Steroid-dependent nephrotic syndrome in children: Histopathology and relapses after cyclophosphamide treatment. *Kidney International*, Vol. 19 (1981), pp. 454-459
9. Cammas B, Harambat J, Bertholet-Thomas A, Bouissou F, Morin D, Guignon V, et al. Long-term effects of cyclophosphamide therapy in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. *Nephrol Dial Transplant* (2011) 26: 178–184

10. Vester U, Zimmermann BK, Hoyer PF. Cyclophosphamide in steroid-sensitive nephrotic syndrome: outcome and outlook. *Pediatr Nephrol* (2003) 18:661–664
11. Shatat IF, Becton LJ, Woroniecki RP. Hypertension in Childhood Nephrotic Syndrome. *Front. Pediatr.* 7;287:1-8.
12. Hari P, Khandelwal P, Smoyer WE. Dyslipidemia and cardiovascular health in childhood nephrotic syndrome. *Pediatric Nephrology*. 2019:1-19.
13. Thalgahagoda RS, Jayaweera AHM, Illangasekera YA, Abeyagunawardena AS. The effect of alternate-day corticosteroids on linear growth in childhood nephrotic syndrome. *Asia Pac J Paediatr Child Health*. 2019;Vol 2:34-42.
14. Caplan A, Fett N, Rosenbach M, Werth VP, Micheletti RG. Prevention and management of glucocorticoid-induced side effects: A comprehensive review. *J Am Acad Dermatol*. 2017;76:201-7.
15. Batishcheva G, Zhdanova O, Nastausheva Y, Chernov Y. Characteristics of adverse side effects of corticosteroid therapy in children with nephrotic syndrome and methods of pharmacological correction. *Research Results in Pharmacology*. 2019; 5(1): 37-43
16. Vidianty J, Pardede S, Hendarto A, Akib A. Obesity in children with frequent relapse and steroid dependent nephrotic syndrome. *Paediatrica Indonesiana*. 2010;Vol . 50, No. 3.
17. Lew, S., Borum, M.L. and Ing, L.S. 2010, ‘Gastrointestinal Complications of Acute Kidney Injury’, in: Jorres, A., Ronco, C. and Kellum, J. A., *Management of Acute Kidney Problems*, Springer, New York.
18. Yasir M, Goyal A, Bansal P, Sonthalia S. Corticosteroid adverse effects: StatPearls Publishing; 2021. Available from : <https://www.ncbi.nlm.nih.gov/books/NBK554612/> [Accessed 9th May 2021]
19. Sholter DE, Armstrong PW. Adverse effects of corticosteroids on the cardiovascular system. *Can J Cardiol*. 2000 Apr;16(4):505-11. PMID: 10787466.

20. Narain U, Gupta A. Urinary tract infection in children with nephrotic syndrome. *Pediatr Infect Dis J*.2018;37:144-6.
21. Trihono, P., Putri, N. and Pulungan, A. (2013) "Prognostic factors and survivals of children with steroid-resistant nephrotic syndrome", *Paediatrica Indonesiana*, 53(1), pp. 42-9. doi: 10.14238/pi53.1.2013.42-9.
22. Mekahli D, Liutkus A, Ranchin B, Yu A, Bessenay L, Girardin E, Van Damme-Lombaerts R, Palcoux JB, Cachat F, Lavocat MP, Bourdat-Michel G, Nobili F, Cochat P. Long-term outcome of idiopathic steroid-resistant nephrotic syndrome: a multicenter study. *Pediatr Nephrol*. 2009 Aug;24(8):1525-32. doi: 10.1007/s00467-009-1138-5. Epub 2009 Mar 12. PMID: 19280229.
23. Hahn D, Samuel SM, Willis NS, Craig JC, Hobson EM. Corticosteroid therapy for nephrotic syndrome in children. *Cochrane Database Syst Rev*. 2020 Aug 31;2020(8):CD001533. doi: 10.1002/14651858.CD001533.pub6. PMID: 35659203; PMCID: PMC8094227.
24. Huh H, Lee H, Lee JP, Kim DK, Oh S, Oh YK, Kim YS, Lim CS. Factors affecting the long-term outcomes of idiopathic membranous nephropathy. *BMC Nephrol*. 2017 Mar 27;18(1):104. doi: 10.1186/s12882-017-0525-6. PMID: 28347297; PMCID: PMC5369217.
25. Paulina Salas, Viola Pinto, Josefina Rodriguez, Maria Jose Zambrano, Veronica Mericq, "Growth Retardation in Children with Kidney Disease", *International Journal of Endocrinology*, vol. 2013, Article ID 970946, 8 pages, 2013. <https://doi.org/10.1155/2013/970946>
26. Sare Gülfem Özlü, Gülay Demircin, Nazan Tökmeci, Aysun Çaltık Yılmaz, Özlem Aydoğ, Mehmet Bülbül & Ayşe Öner (2015) Long-term prognosis of idiopathic nephrotic syndrome in children, *Renal Failure*, 37:4, 672-677, DOI: [10.3109/0886022X.2015.1010940](https://doi.org/10.3109/0886022X.2015.1010940)
27. Becherucci F, Roperto RM, Materassi M, Romagnani P. Chronic kidney disease in children. *Clin Kidney J*. 2016 Aug;9(4):583-91. doi: 10.1093/ckj/sfw047. Epub 2016 Jun 5. PMID: 27478602; PMCID: PMC4957724.

28. Patnaik, S.K., Kumar, P., Bamal, M. *et al.* Cardiovascular outcomes of Nephrotic syndrome in childhood (CVONS) study: a protocol for prospective cohort study. *BMC Nephrol* **19**, 81 (2018).
<https://doi.org/10.1186/s12882-018-0878-5>
29. Goldstein SL, Graham N, Warady BA, Seikaly M, McDonald R, Burwinkle TM, Limbers CA, Varni JW. Measuring health-related quality of life in children with ESRD: performance of the generic and ESRD-specific instrument of the Pediatric Quality of Life Inventory (PedsQL). *Am J Kidney Dis.* 2008 Feb;51(2):285-97. doi: 10.1053/j.ajkd.2007.09.021. PMID: 18215706.
30. Lee TH, Chen JJ, Wu CY, Yang CW, Yang HY. Hyperuricemia and Progression of Chronic Kidney Disease: A Review from Physiology and Pathogenesis to the Role of Urate-Lowering Therapy. *Diagnostics (Basel)*. 2021 Sep 13;11(9):1674. doi: 10.3390/diagnostics11091674. PMID: 34574015; PMCID: PMC8466342.
31. Dhondup T, Qian Q. Acid-Base and Electrolyte Disorders in Patients with and without Chronic Kidney Disease: An Update. *Kidney Dis (Basel)*. 2017 Dec;3(4):136-148. doi: 10.1159/000479968. Epub 2017 Oct 5. PMID: 29344508; PMCID: PMC5757582.
32. Mitsnefes MM. Cardiovascular disease in children with chronic kidney disease. *J Am Soc Nephrol.* 2012 Apr;23(4):578-85. doi: 10.1681/ASN.2011111115. Epub 2012 Mar 1. PMID: 22383696; PMCID: PMC3312513.
33. Zagury, A., Oliveira, A. L. de ., Montalvão, J. A. A., Novaes, R. H. L., Sá, V. M. de ., Moraes, C. A. P. de ., & Tavares, M. de S.. (2013). Steroid-resistant idiopathic nephrotic syndrome in children: long-term follow-up and risk factors for end-stage renal disease. *Brazilian Journal of Nephrology*, 35(3), 191–199. <https://doi.org/10.5935/0101-2800.20130031>
34. El Shafei AM, Soliman Hegazy I, Fadel FI, Nagy EM. Assessment of Quality of Life among Children with End-Stage Renal Disease: A Cross-Sectional Study. *J Environ Public Health*. 2018 Sep 16;2018:8565498.